2 Steps to Biotech Success: Good Data, Then Raise Capital
It's really important for development-stage biotech companies to produce good clinical-trial data to move their drugs toward approval. But it's equally important for those companies to be able to make it from one data readout to the next -- and that requires capital.
In this video from Motley Fool Live, recorded on Dec. 14, Corinne Cardina, bureau chief of healthcare and cannabis for Fool.com, and Fool.com contributor Brian Orelli discuss the companies that had big stock moves thanks to data presented at the American Society of Hematology (ASH) earlier this month, and why investors shouldn't be worried about their subsequent secondary offerings.
Source Fool.com
